| 摘要 |
<p>A nucleic acid (N1) representing the genome of a virus (SEN (not defined) virus) is new. A nucleic acid (N1) representing the genome of a virus (SEN virus) comprises >= 1 of: (a) an open reading frame (ORF) (N1a) encoding a polypeptide selected from one of 26 defined sequences (given in the specification); (b) one of 70 defined nucleic acid sequences (N1b) (given in the specification); (c) nucleic acid sequences (N1c) with varying homology to N1b; and (d) mutated forms of N1a, N1b, or N1c. Independent claims are also included for the following: (1) a nucleic acid (N2) hybridizing to the complementary strand of one of 8 defined sequences (given in the specification); (2) a vector (V1) comprising N1 and N2; (3) a host cell (C1) transformed with V1; (4) a method (M1) of producing a polypeptide (P1) encoded by N1 and N2 comprising culturing C1; (5) P1 produced by M1 or encoded by N1 and N2; (6) a virus (VIR) carrying the genome represented by N1; (7) a host cell (C2) transfected with VIR; (8) a method (M2) for producing VIR comprising culturing C2; (9) a polypeptide (P2) isolated from viral preparations comprising VIR; (10) an antibody (AB1) or an aptamer recognizing an epitope on P1, P2 or VIR; (11) a derivative of P1 or P2 recognized by AB1; (12) a hybridoma (C3) producing AB1; (13) a fusion protein (P3) comprising P1; (14) a mosaic polypeptide (P4) comprising >= 2 epitopes of P1 or VIR which lacks amino acids between the epitopes in the native SEN virus genome; (15) a solid phase attached to N1 and N2, P1-P4, a derivative of P1 and P2, VIR and AB1; (16) a non-pathogenic derivative of VIR; (17) a vaccine (VAC) comprising N1 and N2, P1-P4, a derivative of P1 and P2, VIR, AB1 and the derivative of VIR; (18) a method (M3) for detecting VIR in a sample comprising hybridizing DNA of the sample with N1 and N2 or V1 and detecting the hybrid or amplifying DNA in the sample using primers and detecting the product; (19) a method (M4) for detecting VIR in a sample using AB1 and detecting the formation of a complex; (20) a method (M5) for detecting AB1 comprising incubating with N1 and N2, P1 and P2, VIR, or the derivative of P1 and P2 and detecting the formation of a complex; (21) a preparation of polyclonal antibodies (AB2) specific to N1 and N2, P1 and P2, or VIR; (22) a method (M6) of producing antibodies to N1 and N2, P1 and P2, a derivative of P1 and P2, or VIR; (23) a method (M7) of immunizing against VIR comprising administration of VAC; (24) a method (M8) of propagating VIR comprising culturing C2; (25) a method (M9) of propagating VIR in an animal; and (26) a method (M10) of treating or preventing a disease in a mammal (human) afflicted with VIR comprising administering an anti-viral agent or AB1. ACTIVITY : Cytostatic; antiinflammatory; hepatotropic, virucide; dermatological; immunosuppressive. No biological data given. MECHANISM OF ACTION : Vaccine.</p> |
